Abstract:Gastrointestinal stromal tumors (GISTs) represent a spectrum of tumors characterized by variable behaviors and activating mutations in KIT proto-oncogene, receptor tyrosine kinase (KIT) or platelet derived growth factor receptor α (PDGFRA) genes. However, whether genotype analysis should be regarded as a prognostic indicator remains unclear. In the present study, clinicopathological data and the mutation phenotypes of KIT and PDGFRA genes were assessed in a series of 302 patients with GISTs at a single center. Univariate and multivariate Cox regression analyses were performed to identify the clinicopathological and mutational factors associated with relapse-free survival (RFS) in patients who had undergone complete primary GIST resection. KIT and PDGFRA mutations were identified in 233 (77.2%) and 30 (9.9%) cases, respectively. The following clinicopathological parameters were significantly associated with a shorter RFS: Male, non-gastric tumor origin, larger tumor size (>5 cm), high mitotic activity (>5/50 high-power fields), necrosis and epithelioid morphology. Tumors at non-gastric sites, with high National Institutes of Health risk classification, high World Health Organization (WHO) grade and KIT deletion involving codons 557/558/559 exhibited a significantly higher risk of progression. In the Cox regression model, KIT deletion involving codons 557/558/559, non-gastric origin and high WHO grade were independent indicators of RFS. The adverse prognosis associated with KIT deletions involving codons 557/558/559 was also observed for gastric GISTs. Conversely, spindle morphology, KIT exon 11 substitution and PDGFRA exon 18 mutation were associated with a longer RFS and lower rate of relapse. Furthermore, the coexistence of KIT exon 11 deletion and exon 13 duplication was observed in one tumor, with adverse prognostic features. Heterogeneity affecting morphology, immunostaining and genotype was identified in 4 cases. In addition, the presence of succinate dehydrogenase-deficient GIST was found in 5 cases (3.6%). In conclusion, the tumor genotype with regard to KIT and PDGFRA mutations exhibited prognostic significance for the risk of GIST progression and may be helpful for the optimization of tailored adjuvant therapy.

Constitutive Activation of Oncogenic PDGFRα-mutant Proteins Occurring in GIST Patients Induces Receptor Mislocalisation and Alters PDGFRα Signalling Characteristics

Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.

Relationship of Plateletderived growth factor receptorαand C-kit gene mutations and expression in gastrointestinal stromal tumors

A study on the mutation and expression of c-kit and PDGFR-α gene in gastrointestinal stromal tumor

PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations

Impact of Kit and Pdgfra Gene Mutations on Prognosis of Patients with Gastrointestinal Stromal Tumors after Complete Primary Tumor Resection

Mutational Characteristics of Gastrointestinal Stromal Tumors: A Single-Center Analysis of 302 Patients

Oncogenic Signaling Mechanisms in Imatinib-Resistant Gastrointestinal Stromal Tumor

Genetic Aberrations Of Gastrointestinal Stromal Tumors

The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).

Relationship Between Gene Mutations and Protein Expressions of PDGFR Α and C-kit in Gastrointestinal Stromal Tumors.

The Oncogenic FIP1L1-PDGFRα Fusion Protein Displays Skewed Signaling Properties Compared to Its Wild-Type PDGFRα Counterpart.

Status and Clinical Analysis of C-Kit and PDGFRA Mutations in the Gastrointestinal Stromal Tumors

Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks

Sustained Mutant KIT Activation in the Golgi Complex Is Mediated by PKC-θ in Gastrointestinal Stromal Tumors

Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors

Intratumoral KIT Mutational Heterogeneity and Recurrent KIT/ PDGFRA Mutations in KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors

Genomic profiling in GIST: Implications in clinical outcome and future challenges

PDGFRA K385 mutants in myxoid glioneuronal tumors promote receptor dimerization and oncogenic signaling

Detection of KIT and PDGFRA Mutations in Gastrointestinal Stromal Tumors

Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research